The Science: Activating the Innate Repair Receptor (IRR)
To understand ARA-290, we first have to talk about the Innate Repair Receptor (IRR). Typically, when your body is under extreme stress, think ischemia, trauma, or chronic metabolic dysfunction, it attempts to signal for help. Traditional EPO (the stuff cyclists used to get in trouble for) binds to a homodimeric receptor to pump out more red blood cells.
But ARA-290 is different. It selectively targets the EPOR–CD131 heterodimer, which is only expressed during tissue injury or high-stress states. By activating this specific pathway, researchers have observed a Revolutionary shift in how the body handles inflammation.
Key Research Highlights:
- Triple-Threat Protection: Research suggests ARA-290 works as a potent anti-inflammatory, anti-apoptotic, and pro-regenerative agent.
- Non-Hematopoietic: Unlike its parent molecule, it doesn’t touch your red blood cell count, making it a much safer subject for long-term tissue research.
- Metabolic Synergy: While its primary fame comes from nerve repair, early Phase II data in Type 2 Diabetes research has shown secondary benefits in HbA1c levels and lipid profiles.
Combatting Neuropathic Pain & Nerve Damage
One of the most exciting frontiers for ARA-290 is its role in Small Fiber Neuropathy (SFN). Whether it’s driven by sarcoidosis or metabolic issues, SFN is notoriously difficult to manage.
Research has shown that subjects receiving a standard research dose of 4mg daily experienced a significant increase in Corneal Nerve Fiber Density (CNFD). This isn’t just masking the pain, it’s research-driven evidence of actual structural regeneration.
When you pair this with our Peptide Calculator, you can see how researchers structure their protocols for maximum efficiency and precision.
